![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The acquisition of Recipharm, to provide innovative drug developers in the Biologics market with differentiated contract development and manufacturing services for ATMPs and builds on the capabilities acquired through GenIbet transaction and acquisition of Vibalogics.
Lead Product(s): Microbiome Therapeutic
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Recipharm AB
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition February 18, 2022